INTRODUCTION
The production of somatostatin by neuroendocrine tumours in diverse locations has been extensively documented [reviewed in Vehmeyer et al. (1985) ]. Tumours in which somatostatin-producing D-cells represent a majority cell type ('somatostatinomas') are rare, but have been found most often in the pancreas (Ganda et al., 1977; Larsson et al., 1977; Krejs et al., 1979; Pipeleers et al., 1979; Wright et al., 1980) . The structure of the biosynthetic precursor of somatostatin (preprosomatostatin) in the human may be deduced from the nucleotide sequence of a cloned cDNA prepared from a human pancreatic tumour (Shen et al., 1982) , and the structure of the gene has been determined from DNA fragments from a human genomic library (Shen & Rutter, 1984) . Human preprosomatostatin is a protein of 116 amino acids that contains the sequence of somatostatin-14 at its C-terminus. In the present investigation, isolation and characterization of peptides representing fragments of prosomatostatin from a pancreatic neuroendocrine tumour has enabled the elucidation of the pathway of post-translational processing of the prohormone.
EXPERIMENTAL Patient details
The patient was a 61-year-old man with a 2-year history of abdominal pain, watery diarrhoea and flushing after exercise. Exploratory laparotomy revealed a tumour (4 cm x 3 cm) in the caudal and corpus regions of the pancreas with numerous metastases in regional lymph nodes and the liver. The fasting plasma concentration of vasoactive intestinal polypeptide was 190 pmol/l (healthy subjects < 2 pmol/1) and the fasting plasma somatostatin level was 367 pmol/l (healthy subjects < 20 pmol/1). After laparotomy, the patient developed a fulminant watery diarrhoea hypokalaemia achlorohydria syndrome (Verner & Morrison, 1974) . In April 1986, the primary tumour was resected, but this reduction in tumour mass did not improve the patient's condition. Subsequent embolization of the hepatic artery resulted in normalization of the patient's diarrhoea and a reduction in the severity of the flush. Treatment with human leucocyte interferon was initiated, and the plasma vasoactive-intestinal-polypeptide levels normalized and the flush disappeared temporarily. Another embolization of the liver was required in December 1986.
Tumour histopathology
Tumour tissue was fixed in neutral-buffered formalin and embedded in paraffin. Immunocytochemistry was performed using the peroxidase-anti-peroxidase technique (Sternberger, 1979) using monoclonal antisera against 5-hydroxytryptamine (Consolazione et al., 1981) and chromogranin A (Lloyd & Wilson, 1983) and polyclonal antisera against other regulatory peptides (El- Salhy, 1984 Tissue from the primary tumour (0.71 g) was placed in liquid N2 immediately after resection and stored at -70°C until time of extraction. The tissue was homogenized while still frozen with ethanol/0.7 M-HCI (3: 1, v/v; 20 ml) with an Ultra-Turrax blender. The homogenate was stirred at 4°C for 16 h, centrifuged (1600 g for 1 h at 4°C) and ethanol removed from the supernatant under reduced pressure. Peptides were isolated from the extract by using Sep-pak C18 cartridges (Waters Associates, Milford, MA, U.S.A.) (Conlon & McCarthy, 1984) . After centrifugation (20000 g for 1 h at 4°C), the supernatant was pumped at a flow rate of 1 ml/min through three Sep-pak cartridges connected in series.
Bound material was eluted with 70% (v/v) (Thim et al. 1987) . The detection limit for amino acid phenylthiohydantoin derivatives was 0.5 pmol. Radioimmunoassay methods Somatostatin was measured using an antiserum directed against the central residues of somatostatin-14 that shows full reactivity with somatostatin-28 (McIntosh et al., 1978) . Vasoactive intestinal polypeptide was measured using an antiserum directed against the N-terminalto-central residues of the porcine peptide (Agoston et al., 1985) . Gastrin-releasing peptide was measured by using an antiserum directed against the C-terminal region of the porcine peptide that shows full reactivity with neuromedin C (Conlon et al., 1986) . All concentrations are expressed relative to synthetic standards from Peninsula Laboratories (Europe) Ltd. (St. Helens, Lancs., U.K.).
RESULTS

Concentrations of regulatory peptides in the tumour extract
The extract of primary tumour tissue contained 49.9 nmol equivalents of somatostatin/g wet weight, 29 pmol equivalents of vasoactive intestinal polypeptide/g and 17 pmol equivalents of gastrin-releasing peptide/g. Immunoreactive substance P and neurokinin A were not detected in the extract. The detection limits for substance P and neurokinin A are 3 fmol/tube and 1 fmol/ tube respectively. Purification of the prosomatostatin-derived peptides
The elution profile on reverse-phase h.p.l.c. of the tumour extract, after concentration on Sep-pak cartridges, is shown in Fig. 1 . The retention times of peaks 1 and 2 suggested possible identity with somatostatin-28-(1-12)-peptide [prosomatostatin-(65-76) -peptide] and somatostatin-14. Peak 2 was the only peak in the chromatogram with somatostatin-like immunoreactivity determined by radioimmunoassay. Peak 3 [prosomatostatin-(1-63)-peptide] was purified to apparent homogeneity on a diphenylmethylsilyl-silica column (Fig. 2) The amino acid compositions of the purified peptides from peaks 1 and 2 (Fig. 1 ) and peak 3 (Fig. 2) are shown in Table 1 . The data confirm that peak 1 is prosomatostatin-(65-76)-peptide and peak 2 is somatostatin-14. The composition of the peptide from peak 3 indicated probable identity with prosomatostatin-(1-63)-peptide. With the exception of a slightly high value for glutamic acid/glutamine and a slightly low value for proline, the agreement between the composition measured and that predicted from the nucleotide sequence of the prepro- somatostatin gene (Shen et al., 1982; Shen & Rutter, 1984) was good. Cleavage of prosomatostatin-(1-63)-peptide with Armillaria mellea proteinase generated five peptide fragments, which were separated by reversephase h.p.l.c. (Fig. 3) . The amino acid compositions of the peptides ( (Table 3 ). The N-terminal sequence of the peptide (Ala-Pro-Ser-Asp) corresponds to residues 25-28 ofpreprosomatostatin. Thus the Gly24-Ala25 bond is identified as the site of cleavage of the signal peptide.
DISCUSSION
The very high level of expression of the preprosomatostatin gene in a pancreatic neuroendocrine Vol. 248 tumour has permitted the isolation of peptides derived lfom prosomatostatin that do not contain the somatostatin-14 sequence. Previous studies have identified somatostatin-14 and prosomatostatin-(65-76)-peptide in human tumour tissue (Patel et al., 1983; Bohlen et al., 1983; Conlon & McCarthy, 1984) , but the present investigation has led to characterization ofthe N-terminal fragment. The identity of prosomatostatin-(1-63)-peptide was confirmed by determination of the amino acid compositions of the peptide fragments generated by digestion with Armillaria mellea proteinase. Although Time (min) Fig. 3 . Reverse-phase h.p.l.c. on a Supelcosil LC-18-DB column of the reaction mixture after digestion of prosomatostatin-
(1-63)-peptide with Armillaria mellea proteinase
The concentration of acetonitrile in the eluting solvent is shown by the broken line. The peptide fragments were identified by amino acid composition (Table 2) the primary specificity of the enzyme is considered to be cleavage at the N-terminal side of lysine residues (Lewis et al., 1978) , cleavage at the N-terminal side of the arginine residue at position 8 in the substrate was observed. In a previous study in which aspartate aminotransferase was digested with the enzyme, cleavage was seen at the site of three arginine residues (Doonan et al., 1975) . In this case, however, cleavages were at the C-terminal side of arginine. As in the rat (Goodman et al., 1983) and pig (Schmidt et al., 1985) , the signal peptide is removed from preprosomatostatin by cleavage at the Gly24-Ala25 bond. Formation of prosomatostatin-(1-63)-peptide requires cleavage at a single arginine residue, and it is probable that the specificity of such cleavages is regulated by conformational features in the prohormone (Schwartz, 1986) . Prosomatostatin-(1-63)-peptide contains three arginine residues, but these sites are not recognized by the processing enzyme(s). The formation of prosomatostatin-(1-63)-peptide and prosomatostatin-(65-76)-peptide indicates the Arg" residue is removed by the action of exopeptidase(s). Previous studies (Conlon et al., 1981; Bohlen et al., 1983) have identified somatostatin-28 in extracts of human pancreatic tumours. The major peaks of u.v.-absorbing material with retention times similar to that of synthetic somatostatin-28 ( Fig. 1) were not associated with somatostatin-like immunoreactivity. It is concluded, therefore, that the concentration of this component in the tumour must be less than 1 nmol/g. Similarly, peptides identified as prosomatostatin-(68-76)-peptide and prosomatostatin-(65-74)-peptide were also isolated from a pancreatic tumour (Conlon & McCarthy, 1984) . These peptides were eluted from a reverse-phase h.p.l.c. column before prosomatostatin-(65-76)-peptide. Consequently, the elution profile shown in Fig. 1 shows either that these metabolites were not present in the tumour extract or that they did not bind to the Sep-pak cartridges during the initial isolation step. Identification of prosomatostatin-(1-63)-peptide does not preclude the formation of other peptides derived from preprosomatostatin that were not isolated in this study. The lower yield of prosomatostatin-(65-76)-peptide compared with somatostatin-14 would be consistent with the formation of prosomatostatin-(1-76)-peptide, i.e. the prosomatostatin molecule lacking Arg-Lys-somatostatin-14. This peptide has been isolated from rat brain (Benoit et al., 1984) . On the other hand, the hydrophilic prosomatostatin-(65-76)-peptide does not bind efficiently to the Sep-pak cartridges used in the isolation procedure, so that manipulative losses may be responsible for the low yield. Somatostatin-14 was the only major component in the tumour extract with somatostatin-like immunoreactivity, demonstrating that intact prosomatostatin (residues 1-92) was either absent or present in very low concentrations. Previous studies have demonstrated that prosomatostatin in rat brain (Benoit et al., 1984) and pig intestine (Schmidt et al., 1985) is cleaved at the Leu32 -Leu33 bond. The extraction methods used in these studies involved, however, boiling in aqueous solution,
and it is possible that this procedure resulted in proteolysis at an unphysiological site. In contrast, the tumour tissue was extracted at low temperature with a 75 % (v/v) ethanolic solution, so that 'artefactual' activation of a protease under these condition is unlikely.
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